TAKESHI MASUDA

Last Updated :2026/05/18

Affiliations, Positions
Hiroshima University Hospital, Associate Professor (Special Recognition)
E-mail
ta-masudahiroshima-u.ac.jp
Self-introduction
Respiratry medicine, Lung cancer

Basic Information

Major Professional Backgrounds

  • 2013/04/01, 2014/03/31, Hiroshima University Hospital, Clinical Fellow
  • 2014/04/01, Hiroshima University Hospital, Assistant Professor

Academic Degrees

  • Doctor of Philosophy in Medical Science, Hiroshima University

In Charge of Primary Major Programs

  • Medicine

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Respiratory organ internal medicine
  • Medicine,dentistry, and pharmacy;Clinical internal medicine;General internal medicine (including psychosomatic medicine)

Research Keywords

  • Respiratory Internal Medicine
  • Clinical Oncology
  • Lung cancer

Educational Activity

Course in Charge

  1. 2026, Undergraduate Education, Year, Clinical diagnosis and treatment I
  2. 2026, Undergraduate Education, First Semester, Internal Medicine II
  3. 2026, Graduate Education (Master's Program) , Second Semester, General Clinical Medicine and Dentistry
  4. 2026, Graduate Education (Doctoral Program) , 1Term, Practice of Oncology

Research Activities

Academic Papers

  1. Tumor-Bearing Status Accelerates Bleomycin-Induced Pulmonary Inflammation via Endothelial Activation, THORACIC CANCER, 17(7), 20260330
    Link to Paper Search Results by DOI
  2. Multicenter Real-World Data on First-Line Chemoimmunotherapy in Patients With Advanced Non-Small Cell Lung Cancer and Performance Status 2: WJOG18424L, CLINICAL LUNG CANCER, 27(3), 212-223, 202604
    Link to Paper Search Results by DOI
  3. Efficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world setting, LUNG CANCER, 214, 202604
    Link to Paper Search Results by DOI
  4. Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer, MOLECULAR CANCER THERAPEUTICS, 25(3), 435-447, 20260302
    Link to Paper Search Results by DOI
  5. A Radiomics-Based Machine Learning Model for Predicting Pneumonitis During Durvalumab Treatment in Locally Advanced NSCLC, AI, 7(1), 20260116
    Link to Paper Search Results by DOI
  6. Role of PAI-1 in the progression and treatment resistance of non-small cell lung cancer, BIOMEDICAL JOURNAL, 49(1), 202602
    Link to Paper Search Results by DOI
  7. Systemic miR-26a deficiency attenuates pulmonary fibrosis via PTEN upregulation and downstream TIMP-1 suppression, MOLECULAR THERAPY NUCLEIC ACIDS, 36(4), 20251209
    Link to Paper Search Results by DOI
  8. Incidence and clinical features of venous thromboembolism in patients with lung cancer in Japan: results from the CS-Lung-003 prospective observational registry study, RESPIRATORY INVESTIGATION, 64(1), 202601
    Link to Paper Search Results by DOI
  9. Exogenous Lipoid Pneumonia Induced by the Excessive Use of Menthol-containing Nasal Inhalers and Subsequent Acute Hypersensitivity Pneumonia Triggered by Domestic Environmental Antigens, INTERNAL MEDICINE, 64(23), 3433-3437, 2025
    Link to Paper Search Results by DOI
  10. Two Cases of Epidermal Growth Factor Receptor L861R Mutation-Positive Lung Adenocarcinoma Treated With Osimertinib and Afatinib, CANCER REPORTS, 8(12), 202512
    Link to Paper Search Results by DOI
  11. Lenvatinib for patients with previously treated advanced thymic carcinoma in real-world settings, ESMO OPEN, 10(6), 202506
    Link to Paper Search Results by DOI
  12. Intensity-Modulated Radiotherapy for Locally Advanced Lung Cancer in the Immunotherapy Era: A Prospective Study WJOG12019L, JTO CLINICAL AND RESEARCH REPORTS, 6(6), 202506
    Link to Paper Search Results by DOI
  13. A Phase II, Open Label, Single-Arm Study on the Efficacy of Cabozantinib in Patients With Advanced/Metastatic Nonsmall Cell Lung Cancer Harboring MET Exon 14 Alterations who Developed Acquired Resistance to Tepotinib or Capmatinib (CAPTURE Trial), CLINICAL LUNG CANCER, 26(3), e232-e235, 202505
    Link to Paper Search Results by DOI
  14. Predictive Value of Circulatory Total VEGF-A and VEGF-A Isoforms for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small-Cell Lung Cancer, CANCERS, 17(4), 202502
    Link to Paper Search Results by DOI
  15. Serum Soluble Toll-Like Receptor 4 is a Predictive Biomarker for Acute Exacerbation and Prognosis of Idiopathic Pulmonary Fibrosis: A Retrospective Study, LUNG, 203(1), 202512
    Link to Paper Search Results by DOI
  16. HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 95(1), 202512
    Link to Paper Search Results by DOI
  17. Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study, LUNG CANCER, 199, 202501
    Link to Paper Search Results by DOI
  18. Efficacy of immune checkpoint inhibitors according to programmed cell death-ligand 1 expression in patients with non-small cell lung cancer and brain metastasis: A real-world prospective observational study, THORACIC CANCER, 15(34), 2408-2417, 202412
    Link to Paper Search Results by DOI
  19. A Case of Granulocyte-Colony-Stimulating Factor-Producing Non-Small Cell Lung Cancer under Steroid Treatment and with Poor Performance Status That Responded to Pembrolizumab, CASE REPORTS IN ONCOLOGY, 17(1), 1115-1123, 2024
    Link to Paper Search Results by DOI
  20. Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer, CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 40, 2024
    Link to Paper Search Results by DOI
  21. Serum soluble isoform of receptor for advanced glycation end product is a predictive biomarker for acute exacerbation of idiopathic pulmonary fibrosis: a German and Japanese cohort study, RESPIRATORY RESEARCH, 25(1), 20241111
    Link to Paper Search Results by DOI
  22. Primary pulmonary extranodal NK/T-cell lymphoma diagnosed by thoracoscopic lung biopsy: A case report, RESPIRATORY MEDICINE CASE REPORTS, 52, 2024
    Link to Paper Search Results by DOI
  23. D-dimer cut-off value for predicting venous thromboembolism at the initial diagnosis in Japanese patients with advanced lung cancer, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 54(9), 1032-1036, 20240520
    Link to Paper Search Results by DOI
  24. Sex-related differences in efficacy of bone marrow-derived high aldehyde dehydrogenase activity cells against pulmonary fibrosis, STEM CELL RESEARCH & THERAPY, 15(1), 20240915
    Link to Paper Search Results by DOI
  25. Prediction of prognosis in lung cancer using machine learning with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND), LUNG CANCER, 194, 202408
    Link to Paper Search Results by DOI
  26. Treatment rationale and protocol design: an investigator-initiated phase II study of combination treatment of nivolumab and TM5614, a PAI-1 inhibitor for previously treated patients with non-small cell lung cancer, JOURNAL OF THORACIC DISEASE, 16(5), 3381-3388, 202405
    Link to Paper Search Results by DOI
  27. Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer, BRITISH JOURNAL OF CANCER, 130(11), 1783-1794, 20240527
    Link to Paper Search Results by DOI
  28. A case of pleural mesothelioma with immunohistochemical staining positive for Krebs von den Lungen-6, RESPIRATORY MEDICINE CASE REPORTS, 50, 2024
    Link to Paper Search Results by DOI
  29. Usefulness of Quantification and Serial Monitoring of Fine Crackles for Early Detection of Treatment-related Lung Injury: A Report of Two Cases, Intern Med. 2024, 2024
  30. A case of pleural mesothelioma with immunohistochemical staining positive for Krebs von den Lungen-6, Respir Med Case Rep., 2024
  31. A Case of Miliary Pulmonary Cryptococcosis Showing Different Changes in Computed Tomography Images of the Left and Right Lungs, Respiratory Endoscopy, 2024
  32. A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC, JTO CLINICAL AND RESEARCH REPORTS, 3(2), 202202
    Link to Paper Search Results by DOI
  33. Lipocalin-2 as a prognostic marker in patients with acute exacerbation of idiopathic pulmonary fibrosis, RESPIRATORY RESEARCH, 25(1), 20240504
    Link to Paper Search Results by DOI
  34. High S100A9 level predicts poor survival, and the S100A9 inhibitor paquinimod is a candidate for treating idiopathic pulmonary fibrosis, BMJ OPEN RESPIRATORY RESEARCH, 11(1), 202402
    Link to Paper Search Results by DOI
  35. Hypoxia-inducible factor 1alpha modulates interstitial pneumonia-mediated lung cancer progression, JOURNAL OF TRANSLATIONAL MEDICINE, 21(1), 20231127
    Link to Paper Search Results by DOI
  36. Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer, SCIENTIFIC REPORTS, 13(1), 20231113
    Link to Paper Search Results by DOI
  37. Nestin and Notch3 collaboratively regulate angiogenesis, collagen production, and endothelial-mesenchymal transition in lung endothelial cells, CELL COMMUNICATION AND SIGNALING, 21(1), 20230921
    Link to Paper Search Results by DOI
  38. Exhaled Nitric Oxide and Olfactory Dysfunction in Patients with Asthma: Association with Chronic Rhinosinusitis, Medicina, 2023
  39. Intestinal overgrowth of Candida albicans exacerbates bleomycin-induced pulmonary fibrosis in mice with dysbiosis, J Pathol., 2023
  40. Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L, Cancer Medicine, 2023
  41. Effect of Dupilumab in a Patient With Severe Asthma Complicated With Recurrent Anaphylaxis: A Case Report, JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 33(3), 230-232, 2023
    Link to Paper Search Results by DOI
  42. Clinical characteristics of extrapulmonary nontuberculous mycobacteria infections in comparison with pulmonary infections: A single-center, retrospective study in Japan, JOURNAL OF INFECTION AND CHEMOTHERAPY, 29(9), 875-881, 202309
    Link to Paper Search Results by DOI
  43. Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility, JAMA NETWORK OPEN, 6(2), 202302
    Link to Paper Search Results by DOI
  44. Prediction model for patient prognosis in idiopathic pulmonary fibrosis using hybrid radiomics analysis, Diagn Interv Imaging, 2022
  45. Serum and bronchoalveolar lavage fluid levels of soluble B7H3 in patients with interstitial lung diseases, RESPIRATORY MEDICINE, 212, 202306
    Link to Paper Search Results by DOI
  46. Predictive value of serum high-mobility group box 1 levels for checkpoint inhibitor pneumonitis, RESPIROLOGY, 28(4), 380-388, 202304
    Link to Paper Search Results by DOI
  47. Preserved ratio impaired spirometry with or without restrictive spirometric abnormality, SCIENTIFIC REPORTS, 13(1), 20230220
    Link to Paper Search Results by DOI
  48. Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial-Mesenchymal Transition, CANCERS, 15(4), 202302
    Link to Paper Search Results by DOI
  49. Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers, Adv Clin Chem ., 112, 2023
  50. Peak expiratory flow, but not tongue pressure, can predict pneumonia development in older adults, Eur Geriatr Med ., 14(1), 211-217, 2023
  51. Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial-Mesenchymal Transition, Cancers (Basel) ., 15(4), 2023
  52. Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study data, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 28(1), 69-78, 202301
    Link to Paper Search Results by DOI
  53. Pre-Existing Interstitial Lung Abnormalities Are Independent Risk Factors for Interstitial Lung Disease during Durvalumab Treatment after Chemoradiotherapy in Patients with Locally Advanced Non-Small-Cell Lung Cancer, CANCERS, 14(24), 202212
    Link to Paper Search Results by DOI
  54. Association of the RAGE/RAGE-ligand axis with interstitial lung disease and its acute exacerbation, RESPIRATORY INVESTIGATION, 60(4), 531-542, 202207
    Link to Paper Search Results by DOI
  55. Association Between Patient Preference for Inhaler Medications and Asthma Outcomes, JOURNAL OF ASTHMA AND ALLERGY, 15, 1539-1547, 2022
    Link to Paper Search Results by DOI
  56. Dupilumab as an adjunct treatment for a patient with steroid-dependent immunoglobulin G4-related disease complicated by asthma: a case report, JOURNAL OF ASTHMA, 59(12), 2395-2401, 20221110
    Link to Paper Search Results by DOI
  57. Predictive role of circulatory levels of high-mobility group box 1 for radiation pneumonitis in patients with non-small cell lung cancer treated with definitive thoracic radiotherapy, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 27(11), 1698-1705, 202211
    Link to Paper Search Results by DOI
  58. Pneumonia and Meningoencephalitis Due to Varicella-zoster Virus Reinfection and Epstein-Barr Virus Reactivation in a Patient with Rheumatoid Arthritis, INTERNAL MEDICINE, 61(19), 2961-2965, 2022
    Link to Paper Search Results by DOI
  59. Incidence of venous thromboembolism in advanced lung cancer and efficacy and safety of direct oral anticoagulants: a multicenter, prospective, observational study (Rising-VTE/NEJ037 study), THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 14, 202207
    Link to Paper Search Results by DOI
  60. Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer, BMC PULMONARY MEDICINE, 22(1), 20220630
    Link to Paper Search Results by DOI
  61. Vocal cord dysfunction detected by a three-dimensional image of dynamic change in respiratory resistance in a patient with difficult-to-treat asthma: a case report, JOURNAL OF ASTHMA, 59(6), 1157-1161, 20220603
    Link to Paper Search Results by DOI
  62. Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L1, THORACIC CANCER, 13(11), 1611-1618, 202206
    Link to Paper Search Results by DOI
  63. Tolerability and efficacy of IMpower133 regimen modified for dialysis patients with extensive-stage small cell lung cancer: Two case reports, THORACIC CANCER, 12(21), 2956-2960, 202111
    Link to Paper Search Results by DOI
  64. A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study, J Hematol Oncol ., 2022
  65. A Case of Pneumonia and Meningoencephalitis Due to Varicella-zoster Virus Reinfection and Epstein-Barr Virus Reactivation in a Patient with Rheumatoid Arthritis., Intern Med., 2022
  66. Primary Pulmonary Mucosa-associated Lymphoid Tissue Lymphoma with the High Expression of IgG4., Intern Med., 2022
  67. Pulmonary Alveolar Proteinosis with Severe Respiratory Failure Improved by Segmental Lung Lavage with Fiberoptic Bronchoscopy under General Anesthesia, INTERNAL MEDICINE, 61(3), 389-393, 2022
    Link to Paper Search Results by DOI
  68. Pneumatosis Intestinalis following Radiation Esophagitis during Chemoradiotherapy for Lung Cancer: A Case Report, CASE REPORTS IN ONCOLOGY, 14(3), 1454-1459, 2021
    Link to Paper Search Results by DOI
  69. Accelerated decline in lung function in adults with a history of remitted childhood asthma, EUROPEAN RESPIRATORY JOURNAL, 59(1), 20220101
    Link to Paper Search Results by DOI
  70. First-line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations, THORACIC CANCER, 13(5), 771-774, 202203
    Link to Paper Search Results by DOI
  71. SK-216, an Inhibitor of Plasminogen Activator Inhibitor-1, Limits Tumor Progression and Angiogenesis, MOLECULAR CANCER THERAPEUTICS, 12(11), 2378-2388, 201311
    Link to Paper Search Results by DOI
  72. MT95-4, a fully humanized antibody raised against aminopeptidase N, reduces tumor progression in a mouse model, CANCER SCIENCE, 106(7), 921-928, 201507
    Link to Paper Search Results by DOI
  73. Histological Quantification of Gene Silencing by Intratracheal Administration of Dry Powdered Small-Interfering RNA/Chitosan Complexes in the Murine Lung, PHARMACEUTICAL RESEARCH, 32(12), 3877-3885, 201512
    Link to Paper Search Results by DOI
  74. Inhibition of Plasminogen Activator Inhibitor-1 Attenuates Transforming Growth Factor-beta-Dependent Epithelial Mesenchymal Transition and Differentiation of Fibroblasts to Myofibroblasts, PLOS ONE, 11(2), 20160209
    Link to Paper Search Results by DOI
  75. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy., Cancer chemotherapy and pharmacology, 67(6), 1465-1469, 2011
  76. Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis, DISEASE MARKERS, 20160517
    Link to Paper Search Results by DOI
  77. Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma, CANCER RESEARCH, 76(11), 3285-3294, 20160601
    Link to Paper Search Results by DOI
  78. Two Cases of Lung Cancer with Carcinomatous Meningitis in Which Erlotinib Was Effective After Gefitinib Therapy, 49, 203-213, 2009
  79. Suplatast tosilate protects the lung against hyperoxic lung injury by scavenging hydroxyl radicals, FREE RADICAL BIOLOGY AND MEDICINE, 106, 1-9, 201705
    Link to Paper Search Results by DOI
  80. Chronic Intestinal Pseudo-obstruction and Orthostatic Hypotension Associated with Small Cell Lung Cancer that Improved with Tumor Reduction after Chemoradiotherapy, INTERNAL MEDICINE, 56(19), 2627-2631, 201710
    Link to Paper Search Results by DOI
  81. Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis., Internal Medicine, 11, 201712
  82. The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer., Cancer Chemother Pharmacology, 201711
  83. Aminopeptidase N/CD13 as a Potential Therapeutic Target in Malignant Pleural Mesothelioma., Eur Respir J, 20180308
  84. AGER rs2070600 polymorphism elevates neutrophil-lymphocyte ratio and mortality in metastatic lung adenocarcinoma, Oncotarget, 55(8), 94382-94392, 20171010
  85. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma., Lung Cancer, 119, 21-24, 2018
  86. Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study, IN VIVO, 32(5), 1155-1160, 201800
    Link to Paper Search Results by DOI
  87. Intratracheal Administration of siRNA Dry Powder Targeting Vascular Endothelial Growth Factor Inhibits Lung Tumor Growth in Mice, MOLECULAR THERAPY-NUCLEIC ACIDS, 12, 698-706, 20180907
    Link to Paper Search Results by DOI
  88. Plasminogen activator inhibitor-1 serves an important role in radiation-induced pulmonary fibrosis, EXPERIMENTAL AND THERAPEUTIC MEDICINE, 16(4), 3070-3076, 201810
    Link to Paper Search Results by DOI
  89. Alternate-day administration of S-1 for elderly patients with advanced non-small-cell lung carcinoma: A prospective feasibility study., Mol Clin Oncol., 9(5), 539-534, 201811
  90. Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study, BMC cancer, 18(1), 1231, 20181210
  91. Serial measurements of KL-6 for monitoring activity and recurrence of interstitial pneumonia with anti-aminoacyl-tRNA synthetase antibody A retrospective cohort study, MEDICINE, 97(49), 201812
    Link to Paper Search Results by DOI
  92. Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1, CANCER LETTERS, 442, 31-39, 201902
    Link to Paper Search Results by DOI
  93. High preoperative C-reactive protein level is a risk factor for acute exacerbation of interstitial lung disease after non-pulmonary surgery, MEDICINE, 98(5), e14296, 201902
    Link to Paper Search Results by DOI
  94. Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma A case report, MEDICINE, 98(12), e14821, 201903
    Link to Paper Search Results by DOI
  95. Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts, JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 23(4), 2984-2994, 201904
    Link to Paper Search Results by DOI
  96. Performance Status Is a Risk Factor for Depression before the Diagnosis of Lung Cancer Patients, INTERNAL MEDICINE, 58(7), 915-920, 201904
    Link to Paper Search Results by DOI
  97. Suplatast tosilate reduces radiation-induced lung injury in mice through suppression of oxidative stress, FREE RADICAL BIOLOGY AND MEDICINE, 136, 52-59, 20190520
    Link to Paper Search Results by DOI
  98. A Case of Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis, Internal Medicine, 58(21), 3129-3131
  99. Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumonia, RESPIRATORY MEDICINE, 152, 44-50, 201906
    Link to Paper Search Results by DOI
  100. A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY), CHEST, 156(2), 357-366, 201908
    Link to Paper Search Results by DOI
  101. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer, RESPIRATORY INVESTIGATION, 57(5), 451-459, 201909
    Link to Paper Search Results by DOI
  102. C-C Motif Chemokine Ligand 15 May Be a Useful Biomarker for Predicting the Prognosis of Patients with Chronic Hypersensitivity Pneumonitis, RESPIRATION, 98(3), 212-220, 201909
    Link to Paper Search Results by DOI
  103. Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer, ANTICANCER RESEARCH, 39(10), 5725-5731, 201910
    Link to Paper Search Results by DOI
  104. Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLC, JOURNAL OF THORACIC ONCOLOGY, 14(12), 2071-2083, 201912
    Link to Paper Search Results by DOI
  105. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 25(1), 74-81, 2020
    Link to Paper Search Results by DOI
  106. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan, LUNG CANCER, 140, 8-18, 202002
    Link to Paper Search Results by DOI
  107. Prospective, randomized, cross-over pilot study of the effects of Rikkunshito, a Japanese traditional herbal medicine, on anorexia and plasma-acylated ghrelin levels in lung cancer patients undergoing cisplatin-based chemotherapy, INVESTIGATIONAL NEW DRUGS, 38(2), 485-492, 202004
    Link to Paper Search Results by DOI
  108. Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer, JOURNAL OF THORACIC DISEASE, 12(3), 1079-1084, 202003
    Link to Paper Search Results by DOI
  109. Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis, RESPIROLOGY, 25(3), 275-280, 202003
    Link to Paper Search Results by DOI
  110. Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis, RESPIRATORY RESEARCH, 21(1), 20200611
    Link to Paper Search Results by DOI
  111. Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR), ESMO OPEN, 5(4), 202007
    Link to Paper Search Results by DOI
  112. Serum high-mobility group box 1 as a predictive marker for cytotoxic chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease, RESPIRATORY MEDICINE, 172, 202010
    Link to Paper Search Results by DOI
  113. Extent of pulmonary fibrosis on high-resolution computed tomography is a prognostic factor in patients with pleuroparenchymal fibroelastosis, RESPIRATORY INVESTIGATION, 58(6), 465-472, 202011
    Link to Paper Search Results by DOI
  114. Coexisting TIF1 gamma-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1 gamma Antibody-positive Dermatomyositis, INTERNAL MEDICINE, 59(20), 2553-2558, 2020
    Link to Paper Search Results by DOI
  115. Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers, JAMA NETWORK OPEN, 3(11), 20201112
    Link to Paper Search Results by DOI
  116. Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non-small cell lung cancer, CANCER SCIENCE, 112(1), 369-379, 202101
    Link to Paper Search Results by DOI
  117. Correlations of forced oscillometric bronchodilator response with airway inflammation and disease duration in asthma, CLINICAL RESPIRATORY JOURNAL, 15(1), 48-55, 202101
    Link to Paper Search Results by DOI
  118. Two Cases of Cranial Nerve Metastasis Treated with Radiotherapy and Chemotherapy in Patients with Lung Adenocarcinoma, CASE REPORTS IN ONCOLOGY, 13(3), 1495-1500, 2020
    Link to Paper Search Results by DOI
  119. Alectinib-induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma, INTERNAL MEDICINE, 60(4), 611-615, 2021
    Link to Paper Search Results by DOI
  120. Concomitant emphysema might increase the false-negative rate of urinary antigen tests in patients with pneumococcal pneumonia: results from a retrospective study, EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 40(4), 871-877, 202104
    Link to Paper Search Results by DOI
  121. Autoantibody Positivity Is a Risk Factor for Chemotherapy-induced Exacerbation of Interstitial Pneumonia in Lung Cancer, ANTICANCER RESEARCH, 41(3), 1497-1506, 202103
    Link to Paper Search Results by DOI
  122. Pulmonary lymphangitic carcinomatosis from recurrent gastric cancer 19 years after primary resection: a case report, CLINICAL JOURNAL OF GASTROENTEROLOGY, 14(2), 484-488, 202104
    Link to Paper Search Results by DOI
  123. Pulmonary arteriovenous malformation exhibiting recanalization >10 years after coil embolization Two case reports, MEDICINE, 99(2), 202001
    Link to Paper Search Results by DOI
  124. Prognostic Significance of EGFR Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care Alone, ANTICANCER RESEARCH, 41(5), 2661-2667, 202105
    Link to Paper Search Results by DOI
  125. Predictive role of circulatory HMGB1 in postoperative acute exacerbation of interstitial lung disease in lung cancer patients, SCIENTIFIC REPORTS, 11(1), 20210512
    Link to Paper Search Results by DOI
  126. Risk factors associated with increased discontinuation rate of trimethoprim-sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study, PULMONARY PHARMACOLOGY & THERAPEUTICS, 67, 202104
    Link to Paper Search Results by DOI
  127. D-dimer can be a diagnostic marker for cisplatin-related aortic thrombosis A case report, MEDICINE, 100(7), 20210219
    Link to Paper Search Results by DOI
  128. A machine-learning based approach to quantify fine crackles in the diagnosis of interstitial pneumonia A proof-of-concept study, MEDICINE, 100(7), 20210219
    Link to Paper Search Results by DOI
  129. IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis, PLOS ONE, 16(6), 20210604
    Link to Paper Search Results by DOI
  130. Quantitative parameters of lymphocyte nuclear morphology in bronchoalveolar lavage fluid as novel biomarkers for sarcoidosis, ORPHANET JOURNAL OF RARE DISEASES, 16(1), 20210703
    Link to Paper Search Results by DOI
  131. Gemcitabine maintenance therapy after gemcitabine and platinum drug chemotherapy for naive stage IIIB/IV squamous cell lung cancer: a phase II study, ANTI-CANCER DRUGS, 32(7), 767-772, 202108
    Link to Paper Search Results by DOI
  132. Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activity, STEM CELL RESEARCH & THERAPY, 12(1), 20210823
    Link to Paper Search Results by DOI
  133. Human bone marrow-derived mesenchymal stromal cells cultured in serum-free media demonstrate enhanced antifibrotic abilities via prolonged survival and robust regulatory T cell induction in murine bleomycin-induced pulmonary fibrosis, STEM CELL RESEARCH & THERAPY, 12(1), 20210916
    Link to Paper Search Results by DOI
  134. Analysis of microRNA Expression in Liquid-Based Cytology Samples May Be Useful for Primary Lung Cancer Diagnosis, AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 156(4), 644-652, 202110
    Link to Paper Search Results by DOI
  135. Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 88(5), 857-865, 202111
    Link to Paper Search Results by DOI
  136. Efficacy of erlotinib and its effects on the quality of life of older patients with epidermal growth factor receptor-mutant non-small cell lung cancer: A prospective, multicenter, dose-modification study, GERIATRICS & GERONTOLOGY INTERNATIONAL, 21(10), 881-886, 202110
    Link to Paper Search Results by DOI
  137. Potential benefits of volumetric modulated arc therapy to reduce the incidence of >= grade 2 radiation pneumonitis in radiotherapy for locally advanced non-small cell lung cancer patients, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 51(12), 1729-1735, 202112
    Link to Paper Search Results by DOI

Invited Lecture, Oral Presentation, Poster Presentation

  1. Biomarker analysis of plasma samples in YAMATO study: a randomized trial assessing switching strategy of osimertinib following afatinib in EGFR-mutated NSCLC (TORG1939/WJOG12919L), Itani H, Yoshioka H, Nakamura A, Sakai K, Nishio K, Yonesaka K, Misumi T, Yokoyama T, Tachihara M, Kanemura H, Akamatsu H, Niho S, Furuya N, Takehara T, Miyamoto S, Masuda T, Ishikawa H, Yamamoto N, Okamoto H, Kurata T, 2025/02, Without Invitation, Japanese
  2. A randomized phase III study of chemoradiotherapy in elderly patients with unresectable locally advanced NSCLC: JCOG1914, Shinno Y, Omori S, Kenmotsu H, Takahashi T, Nomura S, Harada H, Ishikura S, Ando M, Izumi H, Oki M, Masuda T, Yokoyama T, Hosomi Y, Shimokawa T, Murakami S, Kurosaki T, Yoshioka H, Yoshida H, Hirano S, Ohe Y, 2024/03, Without Invitation, English
  3. Efficacy and safety of lenvatinib in patients with chemotherapy-naive advanced or recurrent thymic carcinoma: subgroup analysis of a multicenter retrospective study, Tsugitomi R, Ashinuma H, Shukuya T, Gyotoku H, Sakata S, Mouri A, Miwa H, Tamura Y, Tokito T, Tsukita Y, Kogure Y, Masuda T, Tanaka H, Kubo S, Suzuki T, ESMO Congress 2024, 2024/09, Without Invitation, English, Barcelona
  4. Machine learning prediction of prognosis in lung cancer with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND), Toi Y, Fujimoto D, Hayashi H, Murotani K, Yokoyama T, Katakura S, Yamaguchi T, Tanaka K, Miura S, Tamiya M, Tachihara M, Shukuya T, Tsuchiya-Kawano Y, Sato Y, Ikeda S, Sakata S, Masuda T, Takemoto S, Okamoto I, Yamamoto N, ASCO 2024, 2024/05, Without Invitation, English, Chicago
  5. An Investigator-Initiated Phase II Study of Combination Treatment of Nivolumab and TM5614, A PAI-1 Inhibitor for Previously Treated NSCLC., Masuda T, Hirata T, Sakamoto T, Tsubata Y, Ichihara E, Kozuki T, Shoda H, Fukagawa E, Yoshida T, Fukutani M, Tsuji-Takayama K, Orihashi Y, Hattori N, 2024 World conference of lung cancer, 2024/09, Without Invitation, Japanese, San Diego
  6. Risk Factors for Ir-AEs in Patients with NSCLC Receiving Chemotherapy Combined with a PD-1/PD-L1 Inhibitor or Nivolumab and Ipilimumab, Nomura A, Masuda T, Takao S, Izumi Y, Araki Y, Takayama Y, Masuda K, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Iwamoto H, Senoo T, Shoda H, Ishikawa N, Yamasaki M, Hamada H, Okada M, Hattori N, 2024 World Conference on Lung Cancer, 2024/09, Without Invitation, Japanese, San Diego
  7. Association between Plasminogen Activator Inhibitor-1 & Tolerance against Anti-PD-1 Antibody in Non-Small Cell Lung Cancer, Sumii M, Masuda T, Shimoji K, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Iwamoto H, Hamada H, Hattori N, 2024 World Conference on Lung Cancer, 2024/09, Without Invitation, English
  8. A phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin for concurrent chemoradiotherapy in elderly patients (≥75 years) with unresectable locally advanced NSCLC: JCOG1914, Omori S, Kenmotsu H, Takahashi T, Nomura S, Harada H, Ishikura S, Ando M, Izumi H, Shinno Y, Oki M, Masuda T, Yokoyama T, Hosomi Y, Shimokawa T, Murakami S, Kurosaki T, Yoshioka H, Mitome N, Fukuda H, Ohe Y, the Lung Cancer Study Group in the Japan Clinical Oncology Group., ESMO Congress 2024, 2024/09, Without Invitation, English, Barcelona
  9. A study of lung cancer cases participated in cancer genome medicine at our hospital, Sumii M, Namba M, Tokumo K, Yamauchi M*, Nakahara H*, Urabe Y*, Nelson HC*, Itamura R*, Motonaga M*, Sakamoto S, Yamaguchi K, Masuda T, Fujitaka K, Okamoto W*, Arihiro K*, Hiyama E*, Hattori N, Hinoi T*, Sugiyama K*, 2023/03, Without Invitation, Japanese
  10. The difference in predictive value for checkpoint inhibitor pneumonitis between serum and plasma levels of HMGB1, Yamaguchi K, Tanahashi H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N, 2023/03, Without Invitation, Japanese
  11. The significance of micro-EGFR T790M mutation on EGFR-TKI efficacy in patients with NSCLC: The WJOG13119L study., Sato Y*, Masuda T, Miura S*, Tachihara M*, Hosokawa S*, Nakamura A*, Miyawaki T*, Yoshimine K*, Mori M*, Shiraishi H*, Hamai K, Haratani K*, Maeda S*, Tabata E*, Kitagawa C*, Tanizaki J*, Imai T*, Yamamoto N*, Nakagawa K*, Hattori N, 2022 ASCO Annual Meeting, 2022/06, Without Invitation, English
  12. Phase 2 study of first-line pembrolizumab in elderly patients with non-small cell lung cancer expressing high PD-L1., Hamai K, Masuda T, Fujitaka K, Suzuki T, Matsumoto N, Matsumura M, Isoyama S, Ueno S, Mito M, Yamaguchi K, Sakamoto S, Kawano R*, Masuda K, Nishino R, Ishikawa N, Yamasaki M, Hattori N, 2022 ASCO Annual Meeting, 2022/06, Without Invitation, English
  13. Liquid biopsy detects genomic drivers in non-small cell lung cancer without EGFR mutations by single-plex testing: WJOG13620L, Hazama D*, Uemura T*, Kenmotsu H*, Meano K*, Wakuda K*, Teraoka S*, Kobe H*, Azuma K*, Yamaguchi T*, Masuda T, Yokoyama T*, Otsubo K*, Haratani K*, Hayakawa D*, Oki M*, Takemoto S*, Ozaki T*, Okabe T*, Hata A*, Hashimoto H*, Yamamoto N*, Nakagawa K*, 2022 World Conference of Lung Cancer, 2022/08, Without Invitation, English
  14. Pre-existing interstitial lung abnormalities are independent risk factors for interstitial lung disease during durvalumab treatment after chemoradiotherapy in patients with locally advanced non–small lung cancer., Daido W, Masuda T, Imano N, Matsumoto N, Shoda H, Hamai K, Iwamoto Y, Takayama Y, Mishima S, Matsumura M, Masuda K, Ueno S, Kawase S, Awaya Y, Nishimura Y, Shiota N, Ishikawa N, Yamasaki M, Kitaguchi S, Fujitaka K, Nagata Y, Hattori N, 2022 ASCO Annual Meeting, 2022/06, Without Invitation, English
  15. The associations between patients preference for inhaled medications and asthma control, Nakanishi Y, Iwamoto H, Miyamoto S, Nakao S, Higaki N, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Matsumoto N, Nakashima T, Onari Y, Fujitaka K, Haruta Y, Hamada H, Hozawa S, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11, Without Invitation, English
  16. A case of pulmonary alveolar proteinosis with severe respiratory failure improved by segmental lung lavage with fiberoptic bronchoscopy under general anesthesia, Matsumoto Y, Masuda T, Takahashi H, Hashimoto K, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Ohshimo S, Fujitaka K, Yamasaki M, Hamada M, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11, Without Invitation, English
  17. Clinical characteristics of Preserved Ratio Impaired Spirometry in Japan, Miura S, Iwamoto H, Omori K, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fujitaka K, Hamada H, Yokoyama A, Hattori N, 2021/11, Without Invitation, Japanese
  18. Current status and future challenges of lung cancer genome medicine at our hospital, Namba M, Tokumo K, Yamauchi M, Nakahara H, Urabe Y, Nelson HC, Teratani Y, Kobayashi R, Itamura R, Motonaga M, Sakamoto S, Yamaguchi K, Masuda T, Fujitaka K, Okamoto W, Arihiro K, Hiyama E, Hattori N, Hinoi T, Sugiyama K, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11, Without Invitation, Japanese
  19. Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activity, Takahashi H, Nakashima T, Masuda T, Namba M, Sakamoto S, Yamaguchi K, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N, 2021/11, Without Invitation, Japanese
  20. The role of circulatory high-mobility group box 1 for predicting checkpoint inhibitor pneumonitis caused by anti-PD-1/PD-L1 antibody monotherapy, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11, Without Invitation, English
  21. Autoantibody positivity is a risk factor for chemotherapy-induced exacerbation of interstitial pneumonia in lung cancer, Ito N, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N, 2021/11, Without Invitation, English
  22. Mesenchymal stem cells cultured in serum-free medium suppress murine bleomycin-induced pulmonary fibrosis by enhancing regulatory T cell induction, Takao S, Nakashima T, Masuda T, Namba M, Sakamoto S, Yamaguchi K, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Nakashima A, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11, Without Invitation, English
  23. Involvement of PAI-1 in acquired resistance to osimertinib in EGFR-mutated lung cancer via its association with EMT., Tokumo K, Masuda T, Sakamoto S, Fujitaka K, Hattori N., 2020/10, Without Invitation, Japanese
  24. Clinical significance of BIM deletion polymorphism on chemoradiotherapy in patients with non-small cell lung cancer, Wakabayashi Y, Masuda T, Sakamoto S, Fujitaka K, Hattori N., 2020/10, Without Invitation, English
  25. Prognostic significance of EGFR gene mutation in patients with EGFR mutated non-small cell lung cancer who receive best supportive care alone, Masuda T, Wakabayashi Y, Sakamoto S, Fujitaka K, Hamada H, Hattori N., 2020/10, Without Invitation, English
  26. Decline of lung function in adults with a history of childhood asthma, Miura S, Iwamoto H, Omori K, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fujitaka K, Hamada H, Yokoyama A*, Hattori N, JSA/WAO Joint Congress 2020, 2020/09, Without Invitation, English
  27. Real-world study of prescription pattern of inhaled corticosteroids in adult asthma, Nakanishi Y, Iwamoto H, Nakao S, Higaki N, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Matsumoto N, Nakashima T, Miyamoto S, Onari Y, Fujitaka K, Haruta Y, Hamada H, Hozawa S, Hattori N, JSA/WAO Joint Congress 2020, 2020/09, Without Invitation, English
  28. Correlations of forced oscillometric bronchodilator response with airway inflammation and disease duration in asthma, Higaki N, Iwamoto H, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fujitaka K, Hamada H, Hattori N, JSA/WAO Joint Congress 2020, 2020/09, Without Invitation, English
  29. Pivotal role of the HMGB1/sRAGE axis in drug-induced lung injury in advanced lung cancer with pre-existing interstitial lung disease, Nakao S, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N, 30th International Congress of the European Respiratory Society, 2020/09, Without Invitation, English
  30. IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis, Nakanishi Y, Horimasu Y, Yamaguchi K, Sakamoto S, Masuda T, Nakashima T, Miyamoto S, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N, 30th International Congress of the European Respiratory Society, 2020/09, Without Invitation, English
  31. Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis, Yamaguchi K, Iwamoto H, Mazur W*, Miura S, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N, 30th International Congress of the European Respiratory Society, 2020/09, Without Invitation, English
  32. Increased fraction of small round lymphocyte in BALF is a diagnostic indicator for sarcoidosis, Horimasu Y, Yamaguchi K, Sakamoto S, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N., 30th International Congress of the European Respiratory Society, 2020/09, Without Invitation, English
  33. Difference between pathogenic and inhibitory bacterial florae is associated with acute exacerbation of idiopathic pulmonary fibrosis, Ohshimo S, Nishi H*, Yamaguchi K, Horimasu Y, Masuda T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Kawaguchi H*, Bonella F*, Guzman J*, Costabel U*, Hattori N, Shime N, 30th International Congress of the European Respiratory Society, 2020/09, Without Invitation, English
  34. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-NSCLC cancers, Shimoji K, Masuda T, Nakanishi Y, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N, 2020 ASCO Annual Meeting, 2020/05, Without Invitation, English
  35. Clinical significance of BIM deletion polymorphism on chemoradiotherapy in patients with non-small cell lung cancer, Wakabayashi Y, Masuda T, Nakashima T, Fujitaka K, Yamaguchi K, Sakamoto S, Nishimura Y, Horimasu Y, Miyamoto S, Senoo T, IwamotoH, Ohshimo S, Hamada H, Hattori N, 2020 ASCO Annual Meeting, 2020/05, Without Invitation, English
  36. EGFR gene mutation is not a significant risk factor in patients with EGFR mutated non-small cell lung cancer who receive best supportive care alone, Masuda T, Wakabayashi Y, Shimoji K, Yamaguchi K, Sakamoto S, Nishimura Y, Horimasu Y, Nakashima T, Miyamoto S, Senoo T, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N., 2020 ASCO Annual Meeting, 2020/05, Without Invitation, English
  37. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer, Nakanishi Y, Masuda T, Sakamoto S, Yamaguchi K, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N., The 24th Congress of the Asian Pacific Society of Respirology (APSR 2019), 2019/11, Without Invitation, English
  38. The incidence and risk factors for acute exacerbation of interstitial lung disease after non-pulmonary surgery., Takao S, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N., The 24th Congress of the Asian Pacific Society of Respirology (APSR 2019), 2019/11, Without Invitation, English
  39. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer, Masuda T, Nakanishi Y, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N., The 24th Congress of the Asian Pacific Society of Respirology (APSR 2019), 2019/11/14, Without Invitation, English
  40. Clinical Utility of BALF CCL15 as a prognostic biomarker for Chronic Hypersensitivity Pneumonitis, Watanabe M,Horimasu Y, Iwamoto H, Yamaguchi K, Sakamoto S, Masuda T, Nakashima T, Miyamoto S, Ohshimo S, Fujitaka K, Hamada H, Kohno N, Hattori N., European Respiratory Society International Congress 2019, 2019/09/28, Without Invitation, Japanese
  41. Fine crackles quantitative value can help the diagnosis of interstitial lung diseases – Clinical utility of the innovative analyzing system of respiratory sounds, Horimasu Y, Ohshimo S, Yamaguchi K, Sakamoto S, Masuda T, Nakashima T, Miyamoto S, Iwamoto H, Sadamori T*, Fujitaka K, Hamada H, Shime N, Hattori N., 2019/09/28, Without Invitation, English
  42. Serum high mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis, Yamaguchi K, Iwamoto H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N., European Respiratory Society International Congress 2019, 2019/09/28, Without Invitation, English
  43. SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis., Takeshi Masuda, Noboru Hattori, Tadashi Senoo, American Thoracic Society International Conference, San Diego, USA, 2014., 2014, Without Invitation, English
  44. SK-216, an inhibitor of plasminogen activator inhibitor-1, inhibits tumor growth in a mouse model of pleural mesothelioma., Yusuke Takayama, Noboru Hattori, Hironobu Hamada, Takeshi Masuda, American Thoracic Society International Conference, San Diego, USA, 2014., 2014, Without Invitation, English
  45. Gene expression profiles of idiopathic interstitial pneumonitis: Molecular signatures of pulmonary fibrosis, Nobuhisa Ishikawa, Takeshi Masuda, Yasushi Horimasu, Noboru Hattori, Shinichiro Ohshimo, Nobuoki Kohno, 2014, Without Invitation, English
  46. SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis., Takeshi Masuda, Noboru Hattori, Tadashi Senoo, 2014, Without Invitation, English
  47. SK-216, an inhibitor of plasminogen activator inhibitor-1, inhibits tumor growth in a mouse model of pleural mesothelioma., Yusuke Takayama, Noboru Hattori, Hironobu Hamada, Takeshi Masuda, 2014, Without Invitation, English
  48. Anti-tumor Effect of MT95-4, a Fully Humanized Anti-Aminopeptidase N Monoclonal Antibody, on Tumor Progression in an Animal Model of Malignant Pleural Mesothelioma., Takahiko Otsuki, Noboru Hattori, Hironobu Hamada, Horimasu Yasushi, Takeshi Masuda, Taku Nakashima, Iwamoto Hiroshi, Kazunori Fujitaka, Nobuoki Kohno, American Thoracic Society International Conference 2016, 2016/05/13, Without Invitation, English
  49. PAI-1 plays an important role in radiatiopn-induced pulmonary fibrosis, Sachiko Shioya, Noboru Hattori, Takeshi Masuda, Tadashi Senoo, Taku Nakashima, Hiroshi Iwamoto, Kazunori Fujitaka, Nobuoki Kohno, American Thoracic Society International Conference 2016, 2016/05/13, Without Invitation, English
  50. PAI-1 plays an important role in lung cancer progression through the association with differentiation of cancer-associated fibroblasts to myofibroblasts, Takeshi Masuda, Noboru Hattori, Yasushi Horimasu, Kazunori Fujitaka, Hironobu Hamada, American Thoracic Society　International Conference 2016, 2016/05/13, Without Invitation, Japanese
  51. Decreased circulatory receptor for advanced glycation end-products is associated with poorer survival in patients with idiopathic pulmonary fibrosis, Kakuhiro Yamaguchi, Hiroshi Iwamoto, Yasushi Horimasu, Takeshi Masuda, Taku Nakashima, Shintaro Miyamoto, Shinichiro Ohshimo, Kazunori Fujitaka, Noboru Hattori, Witold Mazur, Nobuoki Kohno., 2016/04/10, Without Invitation, English
  52. PAI-1 plays an important role in lung cancer progression through the association with differentiation of cancer-associated fibroblasts to myofibroblasts, Takeshi Masuda, Noboru Hattori, Yasushi Horimasu, Kazunori Fujitaka, Hironobu Hamada, 2016/10/06, Without Invitation, English
  53. Airway reversibility assessed by oscillometry in patients with asthma, Higaki N, Iwamoto H, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fjitaka K, Hamada H, Hattori N, ERS Milan 2017 International Congress, 2017/09/09, Without Invitation, English, European Respiratory Society, Milan, Italy
  54. PAI-1 Influences the Effectiveness of Chemotherapy Through Its Association with Apoptosis in Cancer-Associated Myofibroblasts, T. Masuda. T. Nakashima , M. Namba , K. Yamaguchi , S. Sakamoto , Y. Horimasu , S. Miyamoto , H. Iwamoto , K. Fujitaka , H. Hamada , N. Hatttori, American Thoracic Society 2018 International Conference", 2018/05/18, Without Invitation, English
  55. Vascular Endothelial Growth Factor Knockdown by Intratracheal Administration of Small-Interfering RNA Dry Powder Inhibits Tumor Growth in a Mouse Lung Metastasis Model, K. Miyata. Y. Horimasu , T. Masuda , S. Miyamoto , T. Nakashima , H. Iwamoto , K. Fujitaka , H. Hamada , N. Hattori, American Thoracic Society 2018 International Conference, 2018/05/18, Without Invitation, English, Sandiego, USA
  56. Extent of the Honeycombing Area and the Presence of Traction Bronchiectasis Are Risk Factors for Poorer Prognosis in Patients with Pleuroparenchymal Fibroelastosis, M. Namba. T. Masuda , K. Yamaguchi , S. Sakamoto , Y. Horimasu , S. Miyamoto , T. Nakashima , H. Iwamoto , S. Ohshimo , K. Fujitaka , H. Hamada , N. Hattori, American Thoracic Society 2018 International Conference, 2018/05/18, Without Invitation, English, Sandiego, USA
  57. IPFの遺伝子素因　MUC5B遺伝子多型を中心に, 堀益 靖, 山口 覚博, 坂本 信二郎, 益田 武, 中島 拓, 岩本 博志, 藤高 一慶, 服部 登, 第58回日本呼吸器学会学術講演会, 2018/04/27, Without Invitation, Japanese
  58. Pleuroparenchymal fibroelastosisと特発性肺線維症の臨床的相違点の検討, 難波将史，益田武，山口覚博，堀益靖，宮本真太郎，中島拓，岩本博志，藤高一慶，濱田泰伸，服部登, 2018/04/13, Without Invitation, Japanese

Awards

  1. 2019, Interstitial Lung Disease Assembly Education Awardee, APSR, Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer

External Funds

Acceptance Results of Competitive Funds

  1. 2026, 2029
  2. Practical Research for Innovative Cancer Control, 2024//4//1, 2025//3//3
  3. Practical Research for Innovative Cancer Control, 2024//4//1, 2025//3//3
  4. Practical Research for Innovative Cancer Control, 2024//1/1/, 2025//3//3
  5. KAKENHI(Grant-in-Aid for Scientific Research (C)), 2023, 2026
  6. 2023, 2024
  7. 2024, 2026
  8. A phase II, open label, single arm study to assess the efficacy of cabozantinib in patients with advanced/metastatic non-small cell lung cancer harboring MET exon14 alterations, who developed acquired resistance to tepotinib or capmatinib (CAPTURE Trial), 2024, 2026
  9. 2023, 2026
  10. 2021/03, 2023/02
  11. 2020, 2021
  12. 2019, 2019
  13. KAKENHI, 2018, 2020
  14. KAKENHI, 2015, 2017
    Permalink
  15. 2018, 2019
  16. 2015, 2016

Social Activities

History as Peer Reviews of Academic Papers

  1. 2025, International Journal of Lung Cancer, Others
  2. 2026, Respiratory medicine, Others
  3. 2026, Molecular cancer therapeutics, Others
  4. 2025, Internal Medicine, Others
  5. 2025, Internal Medicine, Others
  6. 2025, Internal Medicine, Others
  7. 2025, Internal Medicine, Others
  8. 2025, Respiratory Medicine Case Reports, Others
  9. 2025, Cances, Others
  10. 2025, Cances, Others
  11. 2025, Respiratory Investigation, Others
  12. 2025, Cancer science, Others
  13. 2024, Scientific report, Others
  14. 2024, Respiratory Medicine, Others
  15. 2023, Internal Medicine, Others
  16. 2023, Journal of Thoracic Disease, Others
  17. 2023, Cancers, Others
  18. 2023, Cancers, Others
  19. 2023, BMC pulmonary medicine, Others
  20. 2023, BMC cancer, Others
  21. 2023, Scientific Reports, Others
  22. 2022, Journal of Cancer Research and Clinical Oncology, Others
  23. 2022, Cancers, Others
  24. 2022, BMC cancer, Others
  25. 2022, BMC pulmonary medicine, Others
  26. 2021, Respiratory Investigation, Others
  27. 2021, Internal Medicine, Others
  28. 2021, Respiratory Investigation, Others
  29. 2021, Journal of Thoracic Disease, Others
  30. 2020, Cancer Management and Research, Others
  31. 2020, Journal of Thoracic Disease, Others, 1
  32. 2018, Journal of thoracic disease
  33. 2019, Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, Others
  34. 2018, Japanese Journal of Clinical Oncology
  35. 2020, Histology and Histopathology, Others
  36. 2020, Respiratory Investigation, Others
  37. 2019, BMC Research Notes, Others
  38. 2019, Journal of Thoracic Disease, Others
  39. 2016, Oncotarget, Others
  40. 2018, 気管支学, Others
  41. 2018, Scientific Reports, Others
  42. 2019, OncoTargets and Therapy, Others
  43. 2019, Evidence-Based Complementary and Alternative Medicine, Others
  44. 2013, Cancer Science, Others
  45. 2014, Respiratory Investigation, Others
  46. 2014, Internal Medicine, Others
  47. 2014, Japanese Journal of Clinical Oncology, Others
  48. 2014, Annals of Oncology, Others
  49. 2014, Annals of Oncology
  50. 2015, PLOS ONE, Others
  51. 2016, Oncotarget, Others
  52. 2016, Internal medicine, Others